Genolution Inc. (225220) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.013x

Based on the latest financial reports, Genolution Inc. (225220) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-927.21 Million ≈ $-628.35K USD) by net assets (₩73.39 Billion ≈ $49.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Genolution Inc. - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Genolution Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Genolution Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.

Genolution Inc. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genolution Inc. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Sintercom India Limited
NSE:SINTERCOM
0.040x
Teaminvest Private Group Ltd
AU:TIP
0.063x
Wing Yip Food Holdings Group Limited American Depositary Shares
NASDAQ:WYHG
-0.005x
Leaders Cosmetics Co. Ltd
KQ:016100
0.004x
Pulsenmore Ltd
TA:PULS
-0.196x
Indofarma Tbk
JK:INAF
0.021x
Cadence Opportunities Fund Ltd
AU:CDO
0.000x
Gryphon Digital Mining Inc.
NASDAQ:GRYP
0.080x

Annual Cash Flow Conversion Efficiency for Genolution Inc. (2016–2024)

The table below shows the annual cash flow conversion efficiency of Genolution Inc. from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Genolution Inc..

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩80.29 Billion
≈ $54.41 Million
₩-1.43 Billion
≈ $-970.93K
-0.018x -37.43%
2023-12-31 ₩87.45 Billion
≈ $59.26 Million
₩-1.14 Billion
≈ $-769.54K
-0.013x -109.07%
2022-12-31 ₩94.70 Billion
≈ $64.18 Million
₩13.55 Billion
≈ $9.18 Million
0.143x -54.29%
2021-12-31 ₩82.20 Billion
≈ $55.71 Million
₩25.73 Billion
≈ $17.44 Million
0.313x -58.26%
2020-12-31 ₩61.29 Billion
≈ $41.54 Million
₩45.97 Billion
≈ $31.15 Million
0.750x +2556.06%
2019-12-31 ₩2.64 Billion
≈ $1.79 Million
₩-80.58 Million
≈ $-54.61K
-0.031x -160.85%
2018-12-31 ₩2.94 Billion
≈ $1.99 Million
₩147.49 Million
≈ $99.95K
0.050x -72.00%
2017-12-31 ₩4.00 Billion
≈ $2.71 Million
₩717.13 Million
≈ $485.99K
0.179x +2372.91%
2016-12-31 ₩3.42 Billion
≈ $2.32 Million
₩-27.00 Million
≈ $-18.30K
-0.008x --

About Genolution Inc.

KQ:225220 Korea Biotechnology
Market Cap
$22.90 Million
₩33.78 Billion KRW
Market Cap Rank
#24585 Global
#1815 in Korea
Share Price
₩1870.00
Change (1 day)
-0.95%
52-Week Range
₩1616.00 - ₩2645.00
All Time High
₩10300.23
About

Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more